Insulet Corporation (PODD)

By both methods, the value today (DCF $199 · Multiples $213) exceeds the market price ($140).

Today — fairly valued: at $140 trades ~34.3% below its value discounted to today (~$213); the discount is positive but does not reach the margin of safety we require (≥38%).

At 5 years — Infravalorado: the target price ($265) plus dividends yield above the required average return (10%) — the business compounds.

The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$132.

Educational / informational. Does not constitute investment advice.

The inverse approach: instead of projecting growth to obtain the value, the market price ($140) is taken as given and it solves for what annual owner-earnings growth would need to hold for 5 years for the present value —at the method's rate (4.5%, no-growth terminal)— to equal that price. It is the disconfirmation test: the expectations the price already pays for, contrasted against the method's projection.

The market discounts less growth (6.6%/year) than we project (15.0%/year) → if the base case holds, there is margin: perception is more pessimistic than the estimated reality.

That growth implies ~$0.4 bn of owner earnings in year 5 (vs ~$0.7 bn of our base case). It recalculates if the DCF assumptions are edited.

Year-by-year projection of the selected scenario. From each year, two versions of the flow are derived: growth FCF (operating flow − total capex, the cash surplus) and maintenance FCF (the owner earnings: what the business yields if it only sustains its capacity). The flow is returned almost in full (dividend + buyback) or redeployed into the operation, so that EV stays roughly flat and multiples compress because the metric grows, not because of cash accumulation. The valuation is done on NOPAT (EV/NOPAT). In edit mode, revenue, margins, capex, and exit multiples can be adjusted.

Year 0 = TTM ended 30-Jun-2026 (rolling grid). The year-1 starting point is anchored to the total revenue guidance in the release of 5-Aug-2026 (20-22% in constant currency, already cut from 21-23%): the path starts at 21% rather than extrapolating TTM growth of 29.4%. The guidance carries two anchors -revenue and adjusted earnings per share (guided growth above 25%)- and both were used: year 1 combines guided revenue growth with moderate margin expansion, consistent with the ~100 basis points of adjusted operating margin expansion the company guides. By segment, the guidance is asymmetric: Omnipod in the US (71% of revenue) was cut from 20-22% to 17-19%, while Omnipod international (28% of revenue) was raised from 26-28% to 30-32% -three of four guidance lines went up or held, and the one that came down is the heaviest-, which suggests the market's reaction (the stock's decline) may be over-discounting an execution problem in one segment (retention of type 2 diabetes patients in the first 90 days) against a business that overall keeps accelerating outside the US. Stock-based compensation (SBC) is low against revenue (2.6%) but material against free cash flow (26.5% of FCF, the method's TSLA case): each scenario's operating cash margin (ocfMargin) is presented net of SBC (TTM 16.74% gross - 2.55% of SBC/revenue = 14.19% net), and it is that net margin that feeds the projection's adjusted earnings together with maintenance capex (50% of total capex, which approximates depreciation). Capex runs well above depreciation (2.2x in the TTM) on manufacturing capacity expansion (a new plant in Costa Rica) while revenue grows strongly -consistent with genuine growth capex, not maintenance in disguise (Greenwald, §3). Share repurchases are material in dollars (some US$305 million in the TTM, around 3% of market capitalization) and are modeled with a declining share path (sharesPath) rather than accumulating cash, because they consume most of the available free cash flow. The rate of that path, however, does not come from the amount or from the authorization —which is a ceiling and is only partly executed— but from the net reduction revealed by the period-end shares outstanding series: 70.39 million at 31-Jul-2025 against 69.35 at 29-Jul-2026, that is −1.48% over the last twelve months, against −0.55% a year over two years and −0.22% over three. The gap between the 3% in dollars and the 1.5% in shares is compensation issuance, which absorbs around half the program: the board itself described the March 2025 authorization, of up to US$125 million, as intended to offset dilution from stock-based compensation. The twelve-month window is modeled and not the longer ones because the pace changed level —the company repurchased US$60 million in all of 2025 against US$300 million in the first half of 2026 alone— and all three windows are declared.

Today's elevated multiple is the price of growth: if the business grows, the entry point cheapens on its own going forward (the metric grows while EV stays roughly flat). The exit multiple at 3 years is higher than the terminal at 5 years —at 3 years there is more growth still ahead—, so the value curve shows whether value creation is concentrated in the early or the later years. The required return is applied to the base scenario.

They are valued separately, with their own rationale, and are not incorporated into the base or the verdict (they are excess return). When assigning them value — in Editmode —, the total with optionalities updates live, without moving the base.

The verdict, the base CAGR, and the margin of safety are always calculated on the base; optionalities do not alter them (with optionalities at $0 they do not move).

Each card fixes a required annual return and answers: if the business is worth $265 in 5 years, what is the maximum that can be paid today to obtain that return? Since it now trades at $140, the margin of safety is how much cheaper the market is than that maximum. The three thresholds: 4% covers inflation (the floor), 10% is the long-term average return, and 15% is the level of a great investment.

With a target price of $265 in 5 years and a required return of 4.5% annually, the maximum to pay today is $213. Against the current market price ($140), the margin of safety is 34.3% (trades below the maximum → there is margin) and the total return at that price would be 13.6% annually.

• Entry multiple. The current price implies a multiple below the terminal exit multiple, consistent with the stock's decline.
• Margin of safety. It trades at a real discount to value, though short of the required margin of safety.
• Scenario dispersion. The adverse scenario yields a return near zero, while the favorable scenario exceeds 18% annually -a reasonable asymmetry given the identified catalyst.
• Sensitivity to terminal multiple. The 20x base multiple is within the archetype's 16-22x band, without relying on a multiple expansion outside the historical range.

Each margin over sales, year by year: historical (solid line) → projection (dotted).

• ✓ ROIC exceeds the cost of capital (~10%)
• ✓ CFROIC backs up the ROIC (86%, cash vs. accruals)
• ✓ Healthy balance sheet (low corporate debt)
• ✓ Durable competitive moat (multiple advantages)

• Return on capital. Return on invested capital of ~20% in the TTM, in the exceptional band (≥20%) of the 10% bar.
• Cash generation. TTM operating cash flow of $511.2 million comfortably funds expansion capex without resorting to additional debt.
• Stock-based compensation. SBC low against revenue (2.6%) but material against free cash flow (26.5%), explicitly expensed in the valuation metric.
• Reinvestment runway. The addressable market across type 1, type 2, and basal-only exceeds 15 million people, with pump penetration of only ~40% in type 1 in the U.S.

Annual levels from the official filing (10-K); the % over each bar is the year-over-year (YoY) growth vs the prior year.

The core business driver is active user volume times the Pod's average selling price, but the company does not report exact Pod unit volumes or a quantitative ARPU -the 10-K only states 'more than 600,000 active users' with no historical series. Growth by segment (U.S. vs. international) is the highest-signal breakdown available, and it is the one 2026 guidance treats asymmetrically: U.S. cut on type 2 diabetes attrition, international raised on the strength of recent Omnipod 5 launches.

The % are the annual (year-over-year) growth: each year —historical and projected— vs the prior one; the TTM (trailing 12m) vs the TTM of a year ago, to avoid overlapping windows. The historicals are exact figures from the official filings; the projected years come from the year-by-year model (the intermediate years without their own series are interpolated between the anchors). The projected columns (+1y…+5y) are 12-month windows counted from the TTM close (30-jun-2026): the projection starts from the most recently reported data, not the fiscal year. The projected base is realistic and unbiased — the risk discount is applied at the end, via the required return. The rationale for each metric is in the (i).

• Recent growth. TTM revenue growing 29.4% year over year, with 2026 guidance marking a deliberate deceleration to 20-22%.
• U.S. segment. Guidance cut from 20-22% to 17-19% on type 2 diabetes patient attrition in the first 90 days.
• International segment. Guidance raised from 26-28% to 30-32% in the same release, a signal of acceleration outside the U.S.
• Drug Delivery. Secondary line in structural decline (-12.3% in 2025, guidance of ~-40% for 2026), but only 1.3% of revenue.

• Revenue recurrence. Replacing the Pod every three days generates naturally recurring revenue, tied to the active user base rather than a one-time sale.
• Product differentiation. The tubeless, adhesive design is technologically distinct from established competitors' tubed pumps, protected by patents.
• Channel concentration. Three distributors account for 78% of total 2025 revenue, a high counterparty dependence for a business of this size.
• Single-platform dependence. Practically all revenue comes from Omnipod; there is no line diversification to cushion a product or commercialization failure.
• Operating leverage. Operating margin expands modestly with scale (guidance of ~100 basis points of adjusted margin expansion per year).

Not all debt is equal: only the structural needs refinancing; the rest is operational (self-liquidating).

Structural debt is what is exposed to the contraction phase of the cycle; operational debt (leases, matched funding) self-liquidates with the business.

• ✓Leverage (net debt / EBITDA)Net cash $0 bn
• ✓Interest coverage (EBIT / interest)24.5x
• –Liquidity (current ratio)no data
• ✓Cash quality (CFROIC vs ROIC)CFROIC backs 86% of ROIC
• ✓Value creation (ROIC − 10% bar)+10pp
• !Malinvestment test (capex vs incremental ROIC)Capex/D&A 2.2x
• !Float / working capitalConsumes cash $0 bn (positive WC)
• ✓Dilution (SBC % of revenue + shares)SBC 2.6% of revenue

A traffic-light interpreted by the method (not generic): float (negative WC) adds up, capex is judged by incremental ROIC (malinvestment test), and a lender is not subjected to corporate solvency. The (i) shows the derivation of each number.

• Cash position. Cash of $534.9 million against total debt of $948.4 million, with moderate net debt against TTM operating cash flow.
• Debt structure. Mostly low-coupon convertible notes; the company repurchased $419.9 million of principal in 2025 with a $123.9 million extinguishment loss, reducing the future burden.
• Interest coverage. Net interest expense (~$21 million) is a minor fraction of TTM EBIT of $515.7 million.
• Buyback funding. Share buybacks are funded with operating cash, not additional debt, consistent with the rule against extrapolating credit-funded buybacks.

Who owns the shares — the alignment and whether there is a controlling shareholder.

• Continuity. Recent CEO and CFO change during 2025, disclosed as a key-personnel retention risk in the 10-K.
• Capital allocation. Reinvestment in manufacturing capacity and share buybacks with no dividend or additional debt to fund the buyback.
• Ownership alignment. Directors and executives own less than 1% of shares, low insider ownership.
• Candor on execution. The company openly characterizes the type 2 attrition as an execution challenge in its own release, rather than downplaying it.

• motivated sellers: guidance cut on U.S. revenue due to type 2 diabetes patient attrition in the first 90 days
• market reaction concentrated in a single segment (U.S., 71% of revenue) while the international segment -nearly a third of revenue- saw its guidance raised in the same release
• adjusted earnings per share guidance cut from >30% to >25% growth, an adjustment smaller in magnitude than the drop in price

The source of the discount is identifiable and verifiable: the Aug 5, 2026 release cut U.S. revenue guidance from 20-22% to 17-19% due to type 2 diabetes patient attrition concentrated in the first 90 days of use, which the company itself characterizes as an execution challenge. It is a classic motivated-seller case -the expectation implicit in prior guidance was not met- but the same release raised international guidance from 26-28% to 30-32% and adjusted operating margin guidance was left unchanged (~100 basis points of expansion). That three of four guidance lines were held or improved, while the price fell sharply, is a verifiable over-discounting argument against an identified catalyst -unlike an absence of cause, which the method explicitly distinguishes from missing buyers.

The annual return (CAGR at 5 years) in each scenario, with the total period return below — the margin of safety made visual: upside range wide, downside range narrow.

Even in the bear scenario, the return holds at +1%/year (+7% total): the margin of safety protects the downside. The bull (+19%/year, +136% total) exceeds it comfortably — a favorable asymmetry, with a narrow downside range and a wide upside range.

• Channel concentration. Three unidentified distributors account for 78% of total 2025 revenue, with contracts generally terminable without cause.
• Type 2 execution. Patient attrition in the first 90 days is the central disconfirmer of the thesis and still has no declared resolution.
• Manufacturing concentration. Production at only three locations plus a fourth under construction, with U.S. inventory in a single site in Massachusetts.
• Tariff risk. Ongoing Section 232 investigation into tariffs on imported medical devices, including insulin pumps.
• Rising competitive intensity. The spinoff of Medtronic Diabetes as an independent company and growth from Beta Bionics and Tandem raise competitive pressure.

Each thinker's analytical framework applied to our data.

• Buffett / Graham Quality + margin of safety

  A narrow moat and ROIC 21% above the 10% bar, but the margin is limited (+34%) → excellent business at a fair price.

• Peter Lynch Growth at a reasonable price (GARP)

  A fast grower growing 15% at a multiple/growth of 1.8 → reasonable for its growth.

• Joel Greenblatt Cheap and high-return (Magic Formula)

  Earnings yield 5% (EBIT/EV) + ROIC 21% → brushes the Magic Formula.

• Howard Marks Perception vs reality + cycle

  The price discounts 7% vs our 15%: perception is more pessimistic than reality, with an identified source of the discount.

• Seth Klarman Capital protection (bear scenario)

  Bear-scenario floor +1%/yr, bull-scenario ceiling +19%/yr over 5y → capital protected, asymmetry in your favor.

• Pat Dorsey Moat strength (Five Rules)

  A narrow moat, stable; sources: intangibles, switching costs, cost advantage, efficient scale → partially passes the Five Rules.

• Aswath Damodaran Expectations implied by the price

  Justifying the price requires discounting 7%, within what we project (15%) — the story squares with the numbers.